Prognostic value of ADAMTS13 in patients with severe sepsis and septic shock

Clinical and Investigative Medicine

Volumn 40, Issue 2, 2017, Pages E49-E58

  Feroz Azfar, M ^a   Faisal Khan, M ^a   Shahid Habib, S ^a   Al Aseri, Z ^a   Mohammad Zubaidi, A ^a   Ocampo Aguila, D ^a   Owais Suriya, M ^a   Ullah, Hameed ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMTS13 PROTEIN, HUMAN; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; AGED; APACHE; BLOOD; FEMALE; HUMAN; INTENSIVE CARE UNIT; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SEPSIS; SEPTIC SHOCK; STATISTICS AND NUMERICAL DATA;

ADAMTS13 PROTEIN; ADULT; AGED; APACHE; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SEPSIS; SHOCK, SEPTIC;

EID: 85018178200     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock:2008. Crit Care Med. 2008 Jan; 36(1):296-327.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310.
3. Nduka OO1, Parrillo JE. The pathophysiology of septic shock. Crit Care Clin. 2009 Oct; 25(4):677-702.
4. Hotchkiss RS, Karl IE: Endothelial cell apoptosis in sepsis: a case of habeas corpus? Crit Care Med 2004, 32:901-902.
5. Hotchkiss RS, Tinsley KW, Swanson PE, Karl IE: Endothelial cell apoptosis in sepsis. Crit Care Med 2002, 30:S225-228.
6. Hemmer CJ, Vogt A, Unverricht M, Krause R, Lademann M, Reisinger EC: Malaria and bacterial sepsis: similar mechanisms of endothelial apoptosis and its prevention in vitro. Crit Care Med 2008, 36:2562-2568.
7. Hack CE, Zeerleder S: The endothelium in sepsis: source of and a target for inflammation. Crit Care Med 2001, 29:S21-27.
8. Matsuda N, Teramae H, Yamamoto S, Takano K, Takano Y, Hattori Y: Increased death receptor pathway of apoptotic signaling in septic mouse aorta: effect of systemic delivery of FADD siRNA. Am J Physiol Heart Circ Physiol 2010, 298:H92-101.
9. Xing et al. Clinical utility of biomarkers of endothelialactivation in sepsis-a systematic review Katharine Xing1, Srinivas Murthy2, W Conrad Liles3, 4 and Jeffrey M Singh4, 5* Critical Care 2012, 16:R7.
10. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B (1998) Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339:1578-1584.
11. Tsai HM, Lian ECY. Antibodies to von Willebrand factorcleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998; 339:1585-1594.
12. Zheng X, Nishio K, Majerus EM, Sadler JE. Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13. J Biol Chem. 2003 Aug 8;278(32):30136-41.
13. Ruggeri ZM, Mannucci PM, Lombardi R, Federici AB, Zimmerman TS. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes. Blood. 1982 Jun;59(6):1272-8.
14. Claus RA, Bockmeyer CL, Budde U, Kentouche K, Sossdorf M, Hilberg T et al. Variation in the ratio between vWF factor and its cleaving protease during systemic inflammation and association with severity. Thromb Haemost. 2009 Feb; 101(2):239-47.
15. Kremer Hovinga JA, Lämmle B. Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program. 2012; 2012:610-6.
16. Sadler JE, Moake JL, Miyata T, George JN. Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program. 2004:407-23.
17. Aibar J, Castro P, Espinosa G, Fernández S, Hernández C, Rinaudo M, Butjosa M, Tàssies D, Reverter JC, Nicolás JM. ADAMTS-13 in Critically Ill Patients With Septic Syndromes and Non-Infectious Systemic Inflammatory Response Syndrome. Shock. 2015 Jan 30.
18. Lin JJ Jainn-Jim Lin, Oi-Wa Chan, Hsiang-Ju Hsiao, Yu Wang, Shao-Hsuan Hsia, Cheng-Hsun Chiu. Decreased ADAMTS 13 Activity is Associated With Disease Severity and Outcome in Pediatric Severe Sepsis. Medicine (Baltimore) 2016 Apr; 95(16): e3374.
19. Martin K, Borgel D, Lerolle N, Feys HB, Trinquart L, Vanhoorelbeke K, et al. Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure. Crit Care Med. 2007 Oct;35(10):2375-82.
20. Kremer Hovinga JA1, Zeerleder S, Kessler P, Romani de Wit T, van Mourik JA, Hack CE, ten Cate H et al. ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost. 2007 Nov;5(11):2284-90.
21. Peigne V, Azoulay E, Coquet I, Mariotte E, Darmon M, Legendre P et al. The prognostic value of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13) deficiency in septic shock patients involves interleukin-6 and is not dependent on disseminated intravascular coagulation. Crit Care. 2013 Nov 18; 17(6):R273.
22. Ono T1, Mimuro J, Madoiwa S, Soejima K, Kashiwakura Y, Ishiwata A, Takano K, Ohmori T, Sakata Y. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood. 2006 Jan 15; 107(2):528-34.
23. Xing K1, Murthy S, Liles WC, Singh JM. Clinical utility of biomarkers of endothelial activation in sepsis-a systematic review. Crit Care. 2012 Jan 16; 16(1):R7.
24. Bockmeyer CL, Claus RA, Budde U, Kentouche K, Schneppenheim R, Lösche W, Reinhart K, Brunkhorst FM. Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor. Haematologica. 2008 Jan;93(1):137-40.
25. Morioka C1, Uemura M, Matsuyama T, Matsumoto M, Kato S, Ishikawa M, et al. Plasma ADAMTS13 activity parallels the APACHE II score, reflecting an early prognostic indicator for patients with severe acute pancreatitis. Scand J Gastroenterol. 2008;43(11):1387-96.
26. ClemensL. Bockmeyer, RalfA. Claus, Ulrich Budde, Karim Kentouche et al. Inflammation-Associated ADAMTS13 Deficiency promotes Formation Of Ultra-Large Von Willebrand Factor. Haematologica January 2008 93: 137-140; Doi:10.3324/haematol.11677.
27. Bellomo R, Giantomasso DD. Noradrenaline and the kidney: friends or foes? Crit Care. 2001; 5 (6): 294-298.
28. Varpula M, Tallgren M, Saukkonen K, Voipio-Pulkki LM, Pettilä V. Hemodynamic variables related to outcome in septic shock. Intensive Care Med. 2005 ; 31 ( 8 ): 1066-1071).
29. Axler O. Low diastolic blood pressure as best predictor of mortality in cardiogenic shock but so far no correlation. Crit Care Med. 2013 Nov; 41(11):2644-7.
30. Taylor BC, Wilt TJ, Welch HG. Impact of diastolic and systolic blood pressure on mortality: implications for the definition of "normal". J Gen Intern Med. 2011 Jul; 26(7):685-90).
31. Pal AC, Mukhopadhyay DK, Kundu P. Serum Fibrinogen Profile In Neonatal Septicemia. IOSR Journal of Dental and Medical Sciences. 2013 May-Jun; 7(5): 01-05.
32. Huang SC1, Yang YJ. Septic shock and hypofibrinogenemia predict a fatal outcome in childhood acute acalculous cholecystitis. J Pediatr Gastroenterol Nutr. 2011 Nov; 53(5):548-52.
33. Karim F, Adil SN, Afaq B, Ul Haq A. Deficiency of ADAMTS-13 in pediatric patients with severe sepsis and impact on in-hospital mortality. BMC Pediatr. 2013 Mar 28; 13:44.
34. Albornoz L, Alvarez D, Otaso JC, Gadano A, Salviu J, Gerona S, Sorroche P, Villamil A, Mastai R. Von Willebrand factor could be an index of endothelial dysfunction in patients with cirrhosis: relationship to degree of liver failure and nitric oxide levels. J Hepatol. 1999 30: 451-455.
35. Langley PG, Hughes RD, Williams R (1985) Increased factor VIII complex in fulminant hepatic failure. Thromb Haemostasis. 1985; 54:693-696.
36. Kavakli K. Plasma levels of the von Willebrand factor-cleaving protease in physiological and pathological conditions in children. Pediatr Hemat Oncol. 2002; 19:467-478.
37. Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E Changes in health and disease of the metalloproteinase that cleaves von Willebrand factor. Blood. 2001; 98:2730-2735.
38. Taniguchi S, Hashiguchi T, Ono T, Takenouchi K, Nakayama K, Kawano T et al. Association between reduced ADAMTS13 and diabetic nephropathy. Thromb Res. 2010;125:E310-E316.
39. Sánchez-Luceros A1, Farías CE, Amaral MM, Kempfer AC, Votta R, Marchese C, Salviú MJ, et al. von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women. Thromb Haemost. 2004 Dec; 92(6):1320-6.
40. Bianchi V1, Robles R, Alberio L, Furlan M, Lämmle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood. 2002 Jul 15; 100(2):710-3.
41. Fukushima H1, Nishio K, Asai H, Watanabe T, Seki T, Matsui H et al. Ratio of von Willebrand factor propeptide to ADAMTS13 is associated with severity of sepsis. Shock. 2013 May;39(5):409-14.
42. Hubbard AR, Heath AB, Hovinga JAK. Value Assignment of the proposed WHO 1st International Standard ADAMTS13, Plasma (12/252). Expert Committee on Biological Standardization. Geneva, 13 to 17 October 2014. WHO/BS/2014.2246.